Bioservo Q4’21: Initial Take - Redeye

Redeye's first impressions on the Q4 report from Bioservo earlier this morning. We see a report that is devoid of any significant surprises. As expected, the sales numbers are still small, while Covid still hampers sales efforts. The total operating income and EBIT are marginally below our expectations.

Länk till analysen i sin helhet: https://www.redeye.se/research/833357/bioservo-q421-initial-take?utm_source=finwire&utm_medium=RSS